Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Satellite

Projekt: Typer af projekter

Vis graf over relationer
A randomized, double blind, placebo-controlled, parallel group, multicentre, phase 2a study to assess target engagement, safety and tolerability of AZD4831 in patients with preserved Ejection Fraction (HFpEF).

The primary objective of this study is to evaluate the target engagement of AZD4831 by measuring myeloperoxidase (MPO) specific activity in plasma following ex vivo stimulation of fresh blood samples with zymosan, in patients with heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). Secondly, to evaluate the safety and tolerability of AZD4831 in patients with HFpEF and HFmrEF and the incidence of maculopapular rash grade 3. In addition, the effect of AZD4831 on Coronary Flow Velocity Reserve (CFVR) as a measure of myocardial microvascular function will be evaluated.
StatusIgangværende
Periode01/02/2020 → …
URL2018-002895-42

ID: 59275900